Differences in interleukin-6, tumor necrosis factor, and procalcitonin levels in acute exacerbations of chronic obstructive pulmonary disease patients with and without secretome supplementation

Differences in interleukin-6, tumor necrosis factor, and procalcitonin levels in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) patients with and without secretome supplementation

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230712001

Enrollment

Registered

2023-07-12

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secretome eupplementation acts as an anti-inflammatory and immunomodulator which can be used as an additional therapy in AECOPD patients. Biomarkers interleukin-6 (IL-6), tumor necrosis factor (TNF) and procalcitonin (PCT) level in AECOPD patients. Acute exacerbation of chronic obstructive pulmonary disease patients

Interventions

Intramuscular (IM) injection of 1ml secretome / 12 hours for 6 doses (3 days),standard therapy of AECOPD

Experimental Drug,Active Comparator Drug

secretome + standard therapy of AECOPD,standard therapy of AECOPD

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with acute exacerbation of COPD. Clinical symptoms of COPD exacerbation: worsening of symptoms (increasing shortness of breath, increased amount of sputum, and sputum purulence) compared to daily conditions. 2. Age over 40 years, based on the difference between the day of birth and the last birthday at the time of the study. 3. Willing to participate in the research and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. AECOPD patients requiring ICU care and ventilators. 2. COPD patients with pleural effusion. 3. COPD patients with lung cancer. 4. COPD patients with HIV.

Design outcomes

Primary

Measure	Time frame
interleukin-6 at 4th day of first intervention enzyme linked immunosorbent assay (ELISA),tumor necrosis factor-a at 4th day of first intervention enzyme linked immunosorbent assay (ELISA)	—

Secondary

Measure	Time frame
procalcitonin at 4th day of first intervention enzyme linked immunosorbent assay (ELISA)	—

Countries

Indonesia

Contacts

Public ContactHendrastutik Apriningsih

Sebelas Maret University

hendrasapriningsih@staff.uns.ac.id6282329053363

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026